Cancer vaccine - Centocor

Drug Profile

Cancer vaccine - Centocor

Latest Information Update: 03 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 06 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
  • 10 Jun 2003 This compound is still in active development
  • 10 Jun 2003 Phase-I clinical trials in Colorectal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top